99 related articles for article (PubMed ID: 23615525)
1. On the regulation and activation of JAK2: a novel hypothetical model.
Lee TS
Mol Cancer Res; 2013 Aug; 11(8):811-4. PubMed ID: 23615525
[TBL] [Abstract][Full Text] [Related]
2. Regulation of JAK2 activation by Janus homology 2: evidence from molecular dynamics simulations.
Wan S; Coveney PV
J Chem Inf Model; 2012 Nov; 52(11):2992-3000. PubMed ID: 23033920
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations.
Lee TS; Ma W; Zhang X; Giles F; Kantarjian H; Albitar M
Cancer; 2009 Apr; 115(8):1692-700. PubMed ID: 19195039
[TBL] [Abstract][Full Text] [Related]
4. New insights into the structure and function of the pseudokinase domain in JAK2.
Silvennoinen O; Ungureanu D; Niranjan Y; Hammaren H; Bandaranayake R; Hubbard SR
Biochem Soc Trans; 2013 Aug; 41(4):1002-7. PubMed ID: 23863170
[TBL] [Abstract][Full Text] [Related]
5. Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structure.
Wan X; Ma Y; McClendon CL; Huang LJ; Huang N
PLoS Comput Biol; 2013 Apr; 9(4):e1003022. PubMed ID: 23592968
[TBL] [Abstract][Full Text] [Related]
6. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
[TBL] [Abstract][Full Text] [Related]
7. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor.
Brooks AJ; Dai W; O'Mara ML; Abankwa D; Chhabra Y; Pelekanos RA; Gardon O; Tunny KA; Blucher KM; Morton CJ; Parker MW; Sierecki E; Gambin Y; Gomez GA; Alexandrov K; Wilson IA; Doxastakis M; Mark AE; Waters MJ
Science; 2014 May; 344(6185):1249783. PubMed ID: 24833397
[TBL] [Abstract][Full Text] [Related]
9. Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F.
Bandaranayake RM; Ungureanu D; Shan Y; Shaw DE; Silvennoinen O; Hubbard SR
Nat Struct Mol Biol; 2012 Aug; 19(8):754-9. PubMed ID: 22820988
[TBL] [Abstract][Full Text] [Related]
10. Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core.
Liosi ME; Krimmer SG; Newton AS; Dawson TK; Puleo DE; Cutrona KJ; Suzuki Y; Schlessinger J; Jorgensen WL
J Med Chem; 2020 May; 63(10):5324-5340. PubMed ID: 32329617
[TBL] [Abstract][Full Text] [Related]
11. Uncoupling JAK2 V617F activation from cytokine-induced signalling by modulation of JH2 αC helix.
Leroy E; Dusa A; Colau D; Motamedi A; Cahu X; Mouton C; Huang LJ; Shiau AK; Constantinescu SN
Biochem J; 2016 Jun; 473(11):1579-91. PubMed ID: 27029346
[TBL] [Abstract][Full Text] [Related]
12. Regulation of Jak2 function by phosphorylation of Tyr317 and Tyr637 during cytokine signaling.
Robertson SA; Koleva RI; Argetsinger LS; Carter-Su C; Marto JA; Feener EP; Myers MG
Mol Cell Biol; 2009 Jun; 29(12):3367-78. PubMed ID: 19364823
[TBL] [Abstract][Full Text] [Related]
13. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
[TBL] [Abstract][Full Text] [Related]
14. Negative regulation of Jak2 by its auto-phosphorylation at tyrosine 913 via the Epo signaling pathway.
Funakoshi-Tago M; Tago K; Kasahara T; Parganas E; Ihle JN
Cell Signal; 2008 Nov; 20(11):1995-2001. PubMed ID: 18682290
[TBL] [Abstract][Full Text] [Related]
15. Receptor specific downregulation of cytokine signaling by autophosphorylation in the FERM domain of Jak2.
Funakoshi-Tago M; Pelletier S; Matsuda T; Parganas E; Ihle JN
EMBO J; 2006 Oct; 25(20):4763-72. PubMed ID: 17024180
[TBL] [Abstract][Full Text] [Related]
16. The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor.
Godeny MD; Sayyah J; VonDerLinden D; Johns M; Ostrov DA; Caldwell-Busby J; Sayeski PP
Cell Signal; 2007 Mar; 19(3):600-9. PubMed ID: 17027227
[TBL] [Abstract][Full Text] [Related]
17. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain.
Saharinen P; Vihinen M; Silvennoinen O
Mol Biol Cell; 2003 Apr; 14(4):1448-59. PubMed ID: 12686600
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation.
Sanz A; Ungureanu D; Pekkala T; Ruijtenbeek R; Touw IP; Hilhorst R; Silvennoinen O
PLoS One; 2011 Apr; 6(4):e18522. PubMed ID: 21533163
[TBL] [Abstract][Full Text] [Related]
19. The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.
Ungureanu D; Wu J; Pekkala T; Niranjan Y; Young C; Jensen ON; Xu CF; Neubert TA; Skoda RC; Hubbard SR; Silvennoinen O
Nat Struct Mol Biol; 2011 Aug; 18(9):971-6. PubMed ID: 21841788
[TBL] [Abstract][Full Text] [Related]
20. Jak2: normal function and role in hematopoietic disorders.
Ihle JN; Gilliland DG
Curr Opin Genet Dev; 2007 Feb; 17(1):8-14. PubMed ID: 17208428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
